Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eagle Pharmaceuticals Inc EGRX

Healthcare Biotechnology
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS... see more

Recent & Breaking News (GREY:EGRX)

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

Accesswire January 18, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire January 18, 2024

INVESTOR ALERT: Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

Accesswire January 18, 2024

EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Lead Class Action Lawsuit!

Accesswire January 18, 2024

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 18, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire January 18, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire January 18, 2024

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

PR Newswire January 18, 2024

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

GlobeNewswire January 18, 2024

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

PR Newswire January 18, 2024

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

Newsfile January 17, 2024

EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Lead Class Action Lawsuit!

Accesswire January 17, 2024

INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire January 17, 2024

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Accesswire January 17, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 17, 2024

INVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRX

Accesswire January 17, 2024

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

Accesswire January 17, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals Lawsuit - EGRX

Accesswire January 16, 2024

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire January 16, 2024

INVESTOR ALERT: Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

Accesswire January 16, 2024
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested